Biohaven Ltd. (BHVN)
$11.42-3.30%Close
SELLCRISIS · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.7B
- Beta
- 3.20
- P/E (TTM)
- -2.46
- Short % float
- 22.50%
- Days to cover
- 6.4
- SI change
- -6.8%
- 1W
- -5.46%
- 1M
- -9.65%
- vs SPY 1W
- -5.89%
- vs SPY 1M
- -11.71%
Industry peers
FMP comparable companies · ranked by market cap
- ABCLBUYAbCellera Biologics Inc.$4.0BCRISISQ -6$13.15-0.24%
- PHVSSELLPharvaris N.V.$2.2BCRISISQ 15$31.12-2.82%
- VERASELLVera Therapeutics, Inc.$2.1BCRISISQ 20$29.42-3.35%
- CLDXSELLCelldex Therapeutics, Inc.$2.1BCRISISQ 5$31.00-4.01%
- IMNMSELLImmunome, Inc.$1.8BCRISISQ 18$19.31-8.20%
- XERSBUYXeris Biopharma Holdings, Inc.$1.7BBULLQ -1$10.07-2.49%
- NTLABUYIntellia Therapeutics, Inc.$1.7BRECOVERYQ 3$12.37-5.33%
- ZBIOSELLZenas BioPharma, Inc.$1.7BCRISISQ 14$26.94-4.70%
- IMCRSELLImmunocore Holdings plc$1.5BBEARQ 2$29.55-4.20%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on BHVN?
- LOPJLB’s latest quantitative signal on Biohaven Ltd. (BHVN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is BHVN in?
- Biohaven Ltd. (BHVN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Biohaven Ltd. (BHVN) do?
- Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Pha…